All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
Mahajan, 2021 1.23 [0.34; 4.42]
NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
0.75 [0.54 ; 1.03 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, NIH NIAID ACTT-1, 2020 4 0% 1,928 moderate not evaluable deathsdetailed results CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
Mahajan, 2021 1.23 [0.34; 4.42]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
0.83 [0.67 ; 1.03 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020 7 15% 8,024 moderate not evaluable deaths (time to event analysis only)detailed results GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11]
0.75 [0.50 ; 1.12 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020 4 52% 7,309 moderate not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
0.95 [0.55 ; 1.64 ] CAP-China (Wang et al.), 2020 1 0% 237 NA not evaluable clinical improvementdetailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.17 [0.92 ; 1.49 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 5 71% 2,492 moderate not evaluable clinical improvement (14-day)detailed results CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
1.50 [1.19 ; 1.90 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 4 0% 1,417 moderate not evaluable clinical improvement (28-day)detailed results CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
1.45 [1.18 ; 1.79 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 4 0% 2,082 moderate not evaluable clinical improvement (7-day)detailed results CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
1.27 [1.00 ; 1.60 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 4 0% 1,417 moderate not evaluable clinical improvement (time to event analysis only)detailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.12 [0.95 ; 1.32 ] CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 5 64% 2,492 moderate not evaluable death or ventilationdetailed results SOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10]
0.97 [0.85 ; 1.10 ] SOLIDARITY (remdesivir), 2020 1 0% 5,451 NA not evaluable mechanical ventilationdetailed results GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
Mahajan, 2021 2.27 [0.39; 13.27]
SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23]
0.87 [0.39 ; 1.96 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, SOLIDARITY (remdesivir), 2020 4 29% 5,818 moderate not evaluable recoverydetailed results GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
1.03 [0.83 ; 1.28 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 66% 1,193 moderate not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable serious adverse eventsdetailed results CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
0.67 [0.53 ; 0.85 ] CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020 4 0% 2,080 moderate not evaluable adverse eventsdetailed results GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
1.40 [1.05 ; 1.87 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 4% 784 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.62 [0.23 ; 1.64 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.58 [0.34 ; 0.97 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 6% 1,296 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.97 [0.48 ; 1.93 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 low not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.82 [0.20 ; 3.29 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.02 [0.64 ; 1.61 ] CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 2020 2 0% 1,296 moderate not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-26 19:38 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 95,94,90,91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290